Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?

In the reported quarter, general and administrative (G&A) expenses rose 40% year over year to $22.1 million. The upside was driven by an increase in the company's commercial preparation expenses in anticipation of a potential FDA approval for Kresladi in severe LAD-I. A month has gone by since the last earnings report for Rocket Pharmaceuticals (RCKT) . Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release ...